Evaluation of a BioRad Avidity assay for identification of recent HIV-1 infections using dried serum or plasma spots.


Journal

Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839

Informations de publication

Date de publication:
04 2019
Historique:
received: 29 11 2018
revised: 01 02 2019
accepted: 06 02 2019
pubmed: 11 2 2019
medline: 7 3 2020
entrez: 11 2 2019
Statut: ppublish

Résumé

Serological methods to differentiate between recently acquired and established HIV-1 infections are a useful tool in the HIV-surveillance to characterize the epidemic, identify groups at risk and assess HIV-preventive interventions. Therefore, an avidity-based, modified BioRad Genscreen™ HIV-1/2 assay (BRA

Identifiants

pubmed: 30738741
pii: S0166-0934(18)30560-3
doi: 10.1016/j.jviromet.2019.02.002
pii:
doi:

Substances chimiques

HIV Antibodies 0

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114-120

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Andrea Hauser (A)

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany; Charité, Universitätsmedizin, Berlin, Berlin, Germany. Electronic address: hauserandrea@gmx.net.

Matthias An der Heiden (MA)

Division of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.

Karolin Meixenberger (K)

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany.

Orjin Han (O)

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany; School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, South Korea.

Stefan Fiedler (S)

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany.

Kirsten Hanke (K)

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany.

Uwe Koppe (U)

Division of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.

Alexandra Hofmann (A)

Division of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany; Charité, Universitätsmedizin, Berlin, Berlin, Germany.

Viviane Bremer (V)

Division of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.

Barbara Bartmeyer (B)

Division of HIV/AIDS, STI and Blood-borne Infections, Robert Koch Institute, Berlin, Germany.

Claudia Kuecherer (C)

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany.

Norbert Bannert (N)

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany; Charité, Universitätsmedizin, Berlin, Berlin, Germany. Electronic address: bannertn@rki.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH